drugset / Trial / NCT07104565
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
Timeline
- Start
- 2025-12-29
- Primary completion
- 2027-09-23
- Completion
- 2028-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tafasitamab | Monoclonal antibody | — | Intravenous |